MAP2K7 and hepatocellular carcinoma: Overall, while it remains to be determined whether such a combination therapy may be efficacious in the clinical setting, our investigation provides solid preclinical data to support the further investigation of anti-MEK and mTOR based therapies for HCC treatment.